Latest Articles in Cardio
-
Cardio Dynamics Gains Support for Vermed Sale
CardioDynamics International has reported that it is progressing with its shareholders’ approval for the sale of its Vermed business unit. The company reached an agreement to sell the Vermed unit to the subsidiary's management team for a cash purchase price of $8 million in late June this year. Vermed is a supplier of disposable electrodes and related...
READ MORE -
Emerging Technology for Personalised Cardiovascular Risk Prediction: Preventing & Managing CVD
Cardiovascular disease (CVD) is responsible for half of all deaths in Europe every year and 25% of chronic disease burden. Aside from the direct effects on human health and welfare CVD costs the European economy over €169 billion per year. The scale of the problem in human and fiscal terms means that urgent action is required to reduce the CVD...
READ MORE -
Handheld Echocardiography: Easy as Child’s Play?
Portable echocardiography has the capacity to identify defects with comparable accuracy to standard machines, to change diagnoses and treatment and has facilitated early discharge in up to 50% of patients. While these figures may depend on the nature and profile of the patients screened and the skills available, in principal it validates the increased...
READ MORE -
Cardiology Requirements for PACS: Defining Future Needs
The Robert Bosch Krankenhaus was opened in 1973 and has created a worldwide reputation in medical and surgical care, for pioneering the practical application of innovative IT solutions to improve healthcare delivery. In my position as "Oberarzt", a function that is somewhere between consultant and registrar, I am responsible for our ten-bed intensive...
READ MORE -
Live 3D Ultrasound Solutions: Accuracy Key for Improved Heart Failure Management
Heart failure, the inability of the heart to pump sufficient blood to meet the metabolic demand of the body, impacts millions worldwide every year. Implications of heart failure are broad and have become a tremendous economic burden. Worldwide, heart failure affects nearly 23 million patients. In Europe, nearly 14 million people suffer from heart...
READ MORE -
First Patient Enrolled in Clinical Trial to Study Drug Sluting Stent Treatment in Women
Abbott has announced that the first patient was enrolled in its Xience V Spirit Women clinical trial, the world’s first clinical trial designed to study the safety and effectiveness of drug eluting stent treatment in women. Liliana Grinfeld, M.D., of the Hospital Italiano in Buenos Aires, Argentina, performed the first procedure. The goal of the trial...
READ MORE -
Medtronic Announces European Introduction of Cardiac Monitor
Medtronic has announced the European introduction of Reveal® XT, the first Insertable Cardiac Monitor that offers longterm and continuous monitoring of Atrial Fibrillation (AF). All other current monitoring tools are either for a limited period or on an intermittent basis. Longterm, continuous monitoring means that a clinician no longer needs to rely...
READ MORE -
Millar Launches World's Smallest Sensor Tip Pressure-Volume Catheter
Millar Instruments, developer and manufacturer of Mikro-Tip® pressure transducer catheters and pressure-volume (P-V) systems, today announced the expansion of its French catheter line with the introduction of the PVR-1045 pressure-volume catheter. With a catheter tip size of 1F (1/3 mm), the PVR-1045 is the smallest and least invasive sensor tip pressure-volume...
READ MORE -
Boston Scientific to Explore Sale of Cardiac & Vascular Surgery Businesses
Boston Scientific announced it intends to explore the sale of its cardiac surgery and vascular surgery businesses as part of its plan to review its portfolio of assets and divest those considered nonstrategic, and to strengthen its operating and financial performance. Paul LaViolette, chief operating officer of Boston Scientific noted that if finalised,...
READ MORE -
Sanofi-Aventis Announces Approval of Labelling Update of Acomplia® in Europe
Sanofi-Aventis announced that the Committee for Medicinal Products for Human Use (CHMP), after re-evaluation, confirms the positive benefit-risk profile of rimonabant in the indicated patient population and has issued a positive opinion on the labelling update. Acomplia® labelling has been updated based on data reflecting one year of post-marketing...
READ MORE
INFO
IMAGING
ICU
EXEC
IT
CARDIOLOGY
JOURNALS
EVENTS
FACULTY
PARTNERS
BLOG
VIDEOS
CONTACT US
